Evidence map›Paper›PMID 38620471›Full record

ArticleNeurologia (Barcelona, Spain)2021

[Three-month functional prognosis of patients hospitalised due to acute ischaemic stroke in Aragon: Rregional analysis of the impact of COVID-19].

H Tejada Meza, Á Lambea Gil, C Villar Yus, C Pérez Lázaro, M P Navarro Pérez, I Campello Morer, Á Giménez Muñoz, J Artal Roy, O Alberti González, N Hernando Quintana and 8 more

Open access · goldAbstract readEnglish Abstract
In one paragraph

Article in Neurologia (Barcelona, Spain), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

H Tejada MezaSección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, España.
Á Lambea GilInstituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España.
C Villar YusSección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, España.
C Pérez LázaroInstituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España.
M P Navarro PérezInstituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España.
I Campello MorerServicio de Neurología, Hospital Royo Villanova, Zaragoza, España.
Á Giménez MuñozServicio de Neurología, Hospital Royo Villanova, Zaragoza, España.
J Artal RoyServicio de Neurología, Hospital San Jorge, Huesca, España.
O Alberti GonzálezServicio de Neurología, Hospital San Jorge, Huesca, España.
N Hernando QuintanaServicio de Neurología, Hospital Obispo Polanco, Teruel, España.
P Ruiz PalominoServicio de Neurología, Hospital Obispo Polanco, Teruel, España.
J A Crespo BurilloServicio de Neurología, Hospital de Barbastro, Barbastro, Huesca, España.
C García ArguedasServicio de Neurología, Hospital de Barbastro, Barbastro, Huesca, España.
L Ballester MarcoServicio de Neurología, Hospital de Alcañiz, Alcañiz, Teruel, España.
M Palacin LarroyServicio de Neurología, Hospital Ernest Lluch, Calatayud, Zaragoza, España.
M Seral MoralServicio de Neurología, Hospital Ernest Lluch, Calatayud, Zaragoza, España.
J Marta MorenoSección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, España.
en nombre del Grupo de Estudio de Enfermedades Neurovasculares-Sociedad Aragonesa de Neurología (GEENV-SARAN)
Hospital Universitario Miguel Servet · ESCentro de Salud Casa del Barco · ESDeleted InstitutionHospital Clínico Universitario Lozano Blesa · ESHospital General San Jorge · ESHospital Obispo Polanco · ESHospital Royo Villanova · ESInstituto de Investigación Sanitaria Aragón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The COVID-19 pandemic has had an impact on ischaemic stroke management, with a reported decrease in hospital admissions, and even disruptions in healthcare and increased in-hospital mortality. However, there is a lack of evidence on the impact of the pandemic on functional prognosis. The aim of this study is to analyse the effect of the COVID-19 pandemic on the 3-month functional outcomes of patients hospitalised due to acute ischaemic stroke in Aragon (Spain). Materil and methods: We reviewed the data of all patients admitted due to ischaemic stroke to any hospital in our regional healthcare system between 30 December 2019 and 3 May 2020. We compared modified Rankin Scale scores and mortality at 3 months in patients hospitalised before and after the declaration of a state of emergency due to the COVID-19 pandemic. Results: In total, 318 patients with acute ischaemic stroke met our inclusion criteria. No differences were observed between periods in global or specific characteristics, with the exception of a higher proportion of patients older than 80 years during the first period (42.2% vs. 29.0%, Conclusion: To our knowledge, this is the first study to analyse the impact of COVID-19 pandemic on the 3-month functional outcomes of patients with ischaemic stroke. In our region, there has been no increase in rates of mortality or disability at 3 months in patients admitted due to ischaemic stroke during the pandemic.

Indexed as

Cerebral infarctionCOVID-19Ischaemic strokeOutcomesSpain

Identifiers

PMID38620471
PMCPMC7901365
OpenAlexW3131928805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.